REGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Company Overview - REGENXBIO Inc. is a leading clinical-stage biotechnology company focused on gene therapy with a mission to improve lives through its curative potential [3] - The company has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines since its founding in 2009 [3] - REGENXBIO is advancing a pipeline of AAV Therapeutics targeting retinal and rare diseases, including collaborations with AbbVie for ABBV-RGX-314 [3] Upcoming Event - REGENXBIO will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on June 12, 2024, at 8:00 a.m. EDT [2] - A live webcast of the event will be available on the Investors section of REGENXBIO's website, with an archived replay accessible for approximately 30 days post-presentation [2] Product Pipeline - The company is developing several AAV Therapeutics, including RGX-202 for Duchenne muscular dystrophy and RGX-121 for MPS II [3] - Thousands of patients have been treated with REGENXBIO's AAV Therapeutic platform, which includes Novartis' ZOLGENSMA for spinal muscular atrophy [3] - AAV Therapeutics are designed as one-time treatments, potentially transforming healthcare delivery for millions [3]